Tiglutik Kit - (50 mg/10 mL; Oral Suspension)

Generic Name	Riluzole	**Innovator**	None
Dosage	50 mg/10 mL; Oral Suspension	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	Less Than 5	**Generic Launches**	None
Indication	TIGLUTIK is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.